Literature DB >> 19932171

Resistance of the dopamine D4 receptor to agonist-induced internalization and degradation.

Anneleen Spooren1, Pieter Rondou, Katarzyna Debowska, Béatrice Lintermans, Linda Vermeulen, Bart Samyn, Kamila Skieterska, Griet Debyser, Bart Devreese, Peter Vanhoenacker, Urszula Wojda, Guy Haegeman, Kathleen Van Craenenbroeck.   

Abstract

Dopamine receptors are G-protein-coupled receptors involved in the control of motivation, learning, and fine-tuning of motor movement, as well as modulation of neuroendocrine signalling. Stimulation of G-protein-coupled receptors normally results in attenuation of signalling through desensitization, followed by internalization and down-regulation of the receptor. These processes allow the cell to regain homeostasis after exposure to extracellular stimuli and offer protection against excessive signalling. Here, we have investigated the agonist-mediated attenuation properties of the dopamine D4 receptor. We found that several hallmarks of signal attenuation such as receptor phosphorylation, internalization and degradation showed a blunted response to agonist treatment. Moreover, we did not observe recruitment of beta-arrestins upon D4 receptor stimulation. We also provide evidence for the constitutive phosphorylation of two serine residues in the third intracellular loop of the D4 receptor. These data demonstrate that, when expressed in CHO, HeLa and HEK293 cells, the human D4 receptor shows resistance to agonist-mediated internalization and down-regulation. Data from neuronal cell lines, which have been reported to show low endogenous D4 receptor expression, such as the hippocampal cell line HT22 and primary rat hippocampal cells, further support these observations. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19932171     DOI: 10.1016/j.cellsig.2009.11.013

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  8 in total

Review 1.  The dopamine D4 receptor: biochemical and signalling properties.

Authors:  Pieter Rondou; Guy Haegeman; Kathleen Van Craenenbroeck
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

Review 2.  Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation.

Authors:  Michelle L Halls
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

3.  The chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, β-arrestin-mediated internalization.

Authors:  C Taylor Gilliland; Catherina L Salanga; Tetsuya Kawamura; JoAnn Trejo; Tracy M Handel
Journal:  J Biol Chem       Date:  2013-09-20       Impact factor: 5.157

4.  Sub-picomolar relaxin signalling by a pre-assembled RXFP1, AKAP79, AC2, beta-arrestin 2, PDE4D3 complex.

Authors:  Michelle L Halls; Dermot M F Cooper
Journal:  EMBO J       Date:  2010-07-27       Impact factor: 11.598

5.  Dopamine receptor D4 internalization requires a beta-arrestin and a visual arrestin.

Authors:  Janise D Deming; Jung-A Shin; Kayleen Lim; Eun-Jin Lee; Kathleen Van Craenenbroeck; Cheryl Mae Craft
Journal:  Cell Signal       Date:  2015-07-11       Impact factor: 4.850

6.  Selective detection of dopamine with an all PEDOT:PSS Organic Electrochemical Transistor.

Authors:  Isacco Gualandi; Domenica Tonelli; Federica Mariani; Erika Scavetta; Marco Marzocchi; Beatrice Fraboni
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.379

7.  Isopeptide and ester bond ubiquitination both regulate degradation of the human dopamine receptor 4.

Authors:  Jennifer C Peeler; Sophia Schedin-Weiss; Mariluz Soula; Manija A Kazmi; Thomas P Sakmar
Journal:  J Biol Chem       Date:  2017-11-03       Impact factor: 5.157

8.  A Split Luciferase Complementation Assay for the Quantification of β-Arrestin2 Recruitment to Dopamine D2-Like Receptors.

Authors:  Lisa Forster; Lukas Grätz; Denise Mönnich; Günther Bernhardt; Steffen Pockes
Journal:  Int J Mol Sci       Date:  2020-08-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.